首页> 外文期刊>PM & R: the journal of injury, function, and rehabilitation >A Novel, Non-opioid Treatment for Chronic Pelvic Pain in Women with Previously Treated Endometriosis Utilizing Pelvic-Floor Musculature Trigger-Point Injections and Peripheral Nerve Hydrodissection
【24h】

A Novel, Non-opioid Treatment for Chronic Pelvic Pain in Women with Previously Treated Endometriosis Utilizing Pelvic-Floor Musculature Trigger-Point Injections and Peripheral Nerve Hydrodissection

机译:具有先前治疗子宫内膜异位症的慢性骨盆疼痛的一种新型,非阿片类药物治疗,利用骨盆底肌肉触发点注射和周围神经水碎

获取原文
获取原文并翻译 | 示例
       

摘要

Background Endometriosis is the abnormal growth of uterine tissue outside the uterine cavity that can cause chronic pain, dysmenorrhea, and dyspareunia. Although the disease is common and nonmalignant in nature, the symptoms can severely impact function and quality of life. Treatment options for endometriosis are limited and not well understood despite a growing need. Objective To determine the effectiveness of pelvic-floor musculature trigger-point injections and peripheral nerve hydrodissection in treating endometriosis symptoms, associated pain, and pelvic functionality. Design Retrospective longitudinal study case series. Setting Private practice. Patients Sixteen female patients with biopsy-confirmed endometriosis. Interventions Ultrasound-guided pelvic-floor trigger-point injections and peripheral nerve hydrodissection performed once a week for 6 weeks. Main Outcome Measurements Pelvic pain intensity as measured pretreatment and posttreatment by the 0 to 10 Visual Analogue Scale (VAS) and the Functional Pelvic Pain Scale (FPPS). Results Pretreatment, the mean VAS score was 6.0 (standard deviation [SD] 2.7), and posttreatment the mean VAS score was 2.9 (SD 2.6); P < .05, 95% confidence interval (CI) 1.16 to 4.97. The mean total FPPS score before treatment was 14.4 (SD 5.2) and posttreatment it was 9.1 (SD 5.8); P < .05, 95% CI 1.34 to 9.28. Analysis of the subcategories within the FPPS indicated that the improvement was statistically significant in the categories of intercourse, sleeping, and working. In the category of intercourse, the mean change in score after treatment was 1.3 (P < .05, 95% CI 0.26-2.31). In the category of sleeping, the mean change in score after treatment was 1.2 (P < .05, 95% CI 0.32-1.99). In the category of working, the mean change in score after treatment was 0.9 (P < .05, 95% CI 0.18-1.53). Conclusions Analysis suggests that the treatment was effective at relieving pain related to endometriosis; it also reflected promise in improving overall pelvic function, particularly in relation to intercourse, working, and sleeping. Level of Evidence IV
机译:背景技术子宫内膜异位症是子宫腔外的子宫组织的异常生长,这可能导致慢性疼痛,痛经和疑难奈。虽然这种疾病本质上是常见和不正常的,但症状可能会严重影响函数和生活质量。尽管需求不断增长,但是子宫内膜异位症的治疗方案是有限的。目的探讨盆地肌肉型触发点注射症和周围神经水池治疗子宫内膜异位症症状,相关疼痛和骨盆功能的有效性。设计回顾性纵向研究案例系列。设置私人惯例。患者患者活组织检查确诊的子宫内膜异位症患者。干预超声引导的骨盆楼触发点注射点注射和周围神经水池每周进行一次持续6周。主要结果测量盆腔疼痛强度,以测量的预处理和0至10个视觉模拟量表(VAS)和功能性盆腔疼痛秤(FPP)进行预处理和后处理。结果预处理,平均VAS得分为6.0(标准偏差[SD] 2.7),后病程平均VAS得分为2.9(SD 2.6); P <.05,95%置信区间(CI)1.16至4.97。治疗前的平均FPPS得分为14.4(SD 5.2)和后处理,其为9.1(SD 5.8); P <.05,95%CI 1.34至9.28。分析FPPS内的子类别表明,改善在性交类别,睡眠和工作的类别中有统计学意义。在性交类别中,治疗后得分的平均变化为1.3(p <.05,95%CI 0.26-2.31)。在睡眠类别中,治疗后得分的平均变化为1.2(P <.05,95%CI 0.32-1.99)。在工作范畴中,治疗后的分数的平均变化为0.9(P <.05,95%CI 0.18-1.53​​)。结论分析表明,治疗有效缓解与子宫内膜异位症相关的疼痛;它还反映了提高整体骨盆功能的承诺,特别是与性交,工作和睡觉有关。证据IV水平

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号